Scarica l'app Stockscreener
41.49
4.93%
1.95
Dopo l'orario di chiusura:
41.49
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Barclays PLC Grows Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
HighTower Advisors LLC Lowers Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Wellington Management Group LLP Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 - Corsicana Daily Sun
Protagonist Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Teachers Retirement System of The State of Kentucky Purchases New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Y Intercept Hong Kong Ltd - MarketBeat
(PTGX) Trading Signals - Stock Traders Daily
Protagonist Therapeutics' SWOT analysis: stock poised for growth amid clinical trials - Investing.com
State Street Corp Boosts Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
XTX Topco Ltd Takes $666,000 Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Clear Street sets $63 target on Protagonist Therapeutics By Investing.com - Investing.com Canada
BNP Paribas Financial Markets Purchases 16,597 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
BTIG maintains shares target on Protagonist Therapeutics, cites trial By Investing.com - Investing.com Australia
HC Wainwright Reiterates "Buy" Rating for Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
Fmr LLC Grows Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist's Rusfertide Shows Breakthrough Results in Phase 2 PV Study: 54% Hit Key Treatment Goals - StockTitan
The Goldman Sachs Group Begins Coverage on Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
Weiss Asset Management LP Makes New $2.81 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Point72 Asset Management L.P. Sells 694,862 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by BMO Capital Markets - MarketBeat
BMO Capital Initiates Coverage of Protagonist Therapeutics (PTGX) with Outperform Recommendation - MSN
Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities - Yahoo Finance
Charles Schwab Investment Management Inc. Buys 39,850 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
(PTGX) Technical Data - Stock Traders Daily
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by RTW Investments LP - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by HighVista Strategies LLC - MarketBeat
Walleye Capital LLC Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Public Sector Pension Investment Board Invests $5.62 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance
Thrivent Financial for Lutherans Invests $2.08 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Intech Investment Management LLC Invests $861,000 in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics chief development officer sells $5.6 million in stock By Investing.com - Investing.com Nigeria
Protagonist Therapeutics CEO sells $4.68 million in stock By Investing.com - Investing.com Nigeria
Protagonist Therapeutics' chief medical officer sells $1.41 million in stock By Investing.com - Investing.com South Africa
Swedbank AB Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics CEO sells $4.68 million in stock - Investing.com India
Protagonist Therapeutics' chief medical officer sells $1.41 million in stock - Investing.com India
Protagonist Therapeutics chief development officer sells $5.6 million in stock - Investing.com
Advantage Alpha Capital Partners LP Acquires Shares of 11,336 Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Protagonist Therapeutics' SWOT analysis: stock poised for growth amid clinical milestones - Investing.com Nigeria
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Objective long/short (PTGX) Report - Stock Traders Daily
Algert Global LLC Sells 36,400 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Eagle Asset Management Inc. - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap UpWhat's Next? - MarketBeat
Victory Capital Management Inc. Has $5.89 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics selects IL-17 antagonist as development candidate - BioWorld Online
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024 - AccessWire
Protagonist Therapeutics CEO to Present at Evercore ISI Healthcare Conference | PTGX Stock News - StockTitan
Pacer Advisors Inc. Increases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate - AccessWire
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):